{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:43:32Z","timestamp":1758476612698},"reference-count":18,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.drugalcdep.2012.05.009","type":"journal-article","created":{"date-parts":[[2012,6,8]],"date-time":"2012-06-08T22:17:41Z","timestamp":1339193861000},"page":"183-188","source":"Crossref","is-referenced-by-count":10,"title":["Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers"],"prefix":"10.1016","volume":"126","author":[{"given":"Manoli","family":"Vourvahis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Mark","family":"Gruener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Douglas","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0005","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1128\/AAC.01455-09","article-title":"Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1","volume":"54","author":"Corbau","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0010","unstructured":"Covidien, 2009. Methadone hydrochloride oral concentrate USP prescribing information. Available at: http:\/\/pharmaceuticals.covidien.com\/imageServer.aspx\/doc191649.pdf?contentID=15861&contenttype=application\/pdf, (accessed November, 2011)."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11531240-000000000-00000","article-title":"Drug interactions with new and investigational antiretrovirals","volume":"49","author":"Crauwels","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0020","series-title":"Poster 109 Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Safety, toleration and pharmacokinetics of single and mulitple oral doses of UK-453,061, a novel NNRTI, in healthy male subjects","author":"Davis","year":"2007"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0025","series-title":"Poster P25 Presented at the 9th IWCPHIV","article-title":"The effect of UK-453,061, a next-generation NNRTI, on the steady state pharmacokinetics of zidovudine, midazolam and contraceptive steroids","author":"Davis","year":"2008"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-012-1287-5","article-title":"The effect of lersivirine (UK-453,061), a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects","author":"Davis","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0035","series-title":"ADMET for Medicinal Chemists: A Practical Guide","author":"Dowty","year":"2011"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/187231208786734067","article-title":"Increase of R-\/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz","volume":"2","author":"Esteban","year":"2008","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0045","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0b013e32832fef5b","article-title":"Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients","volume":"23","author":"F\u00e4tkenheuer","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0050","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1002\/jps.21770","article-title":"Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation","volume":"98","author":"Hassan","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0055","series-title":"Poster 763 Presented at the 15th Conference on Retroviruses and Opportunistic Infections","article-title":"Pharmacokinetic interactions of the next-generation NNRTI UK-453,061 with other antiretrovirals and assessment of safety and tolerability in healthy male subjects","author":"Langdon","year":"2008"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0060","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review","volume":"372","author":"Mathers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0065","series-title":"Abstract 728 Presented at the 15th Conference on Retroviruses and Opportunistic Infections","article-title":"In vitro characterization of UK-453,061, a non-nucleoside reverse transcriptase inhibitor","author":"Mori","year":"2008"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0070","article-title":"HIV-1 reverse transcriptase structure-based drug design: crystals to clinic","volume":"A63","author":"Phillips","year":"2007","journal-title":"Acta Cryst."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0091270007310387","article-title":"Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers","volume":"48","author":"Scholler-Gyure","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","article-title":"Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment","volume":"67","author":"Shiran","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0085","series-title":"Poster Presented at the 10th IWCPHIV","first-page":"15","article-title":"Lack of a clinically relevant effect of UK-453,061, a next generation NNRTI, on the pharmacokinetics of atazanavir\u00b1ritonavir and antacid on the pharmacokinetics of UK-453,061 in healthy subjects","author":"Vourvahis","year":"2009"},{"key":"10.1016\/j.drugalcdep.2012.05.009_bib0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/dmd.109.031252","article-title":"Excretion and metabolism of lersivirine (UK-453,061), a next generation NNRTI, following administration of [14C] lersivirine to healthy volunteers","volume":"38","author":"Vourvahis","year":"2010","journal-title":"Drug Metab. Dispos."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161200172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161200172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T17:54:16Z","timestamp":1542909256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037687161200172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":18,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S037687161200172X"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.05.009","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}